References
- Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, Sinico RA, Sivasothy P, Wechsler ME, Groh M, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48(5):1429–1441. doi:https://doi.org/10.1183/13993003.00097-2016.
- Akuthota P, Weller PF. Spectrum of eosinophilic end-organ manifestations. Immunol Allergy Clin North Am. 2015;35(3):403–411. doi:https://doi.org/10.1016/j.iac.2015.04.002.
- Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: a review. Drugs. 2018;78(8):809–821. doi:https://doi.org/10.1007/s40265-018-0920-8.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:https://doi.org/10.1016/S0140-6736(12)60988-X.
- Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:https://doi.org/10.1056/NEJMoa1403291.
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:https://doi.org/10.1056/NEJMoa1403290.
- Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932. doi:https://doi.org/10.1056/NEJMoa1702079.
- Kahn JE, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, Bletry O. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267–270. doi:https://doi.org/10.1016/j.jaci.2009.10.014.
- Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336–1343. doi:https://doi.org/10.1016/j.jaci.2010.03.028.
- Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341–343. doi:https://doi.org/10.7326/0003-4819-155-5-201109060-00026.
- Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S62–S65.
- Faverio P, Bonaiti G, Bini F, Vaghi A, Pesci A. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy. Ther Clin Risk Manage. 2018;14:2385–2396. doi:https://doi.org/10.2147/TCRM.S159949.
- Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne)). 2018;5:49. doi:https://doi.org/10.3389/fmed.2018.00049.
- Berti A, Cornec D, Casal Moura M, Smyth RJ, Dagna L, Specks U, Keogh KA. Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity. Chest. 2020;157(5):1086–1099. doi:https://doi.org/10.1016/j.chest.2019.11.045.
- Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, Sinico RA, Sivasothy P, Wechsler ME, Groh M, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1–9. doi:https://doi.org/10.1016/j.autrev.2016.09.018.
- Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225. doi:https://doi.org/10.1016/j.anai.2016.10.028.
- Moiseev S, Zagvozdkina E, Kazarina V, Bulanov N, Novikov P. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2019;144(2):621. doi:https://doi.org/10.1016/j.jaci.2019.03.030.
- Thompson G, Vasilevski N, Ryan M, Baltic S, Thompson P. Low-dose mepolizumab effectively treats chronic relapsing eosinophilic granulomatosis with polyangiitis. Respirology. 2018;23(Suppl 1):178. doi:https://doi.org/10.1111/resp.13268.